Delivery Order SPE2DB24D3014-SPE2DB25FKUHH
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,456.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency awarded a $28,019.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pens on August 6, 2025, with completion scheduled for August 7, 2025. The delivery will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $16,728.19 on September 2, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen (0.5 mL) to be delivered to Conshohocken, Pennsylvania. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract is classified as a child award, indicating it is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed price delivery order represents a single-source procurement with no set-aside designation, issued under a competitive contracting mechanism. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and...
- The Defense Logistics Agency (DLA) awarded a $1,904.63 delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on May 5, 2025, with completion expected by May 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $13,060.32 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens with a firm fixed price structure. This delivery order, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation and represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,225.77 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 5, 2025. This competitively awarded, non-set-aside contract has a ceiling value of $3,069.11 and is structured as a firm fixed price delivery order with an ultimate completion date of September 8, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUHHDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,323.06 on August 13, 2025, for the supply of Mounjaro 15 mg/0.5 mL pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 14, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary distribution operations. This delivery order represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. Mounjaro, a diabetes medication, aligns with AmerisourceBergen's demonstrated capability to deliver brand-name pharmaceuticals to federal medical supply chains serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.3k | 8/13/25 |